Young adults with diabetes who experience an acute myocardial infarction tend to see significant health status improvements in the subsequent year and are not significantly worse off than patients who did not have diabetes at the time of acute MI.
The advisory from the American Heart Association aggregates the research performed thus far on the use of omega-3 fatty acids in hypertriglyceridemia and recommends a dose of 4 g/d to observe a therapeutic effect.
Men with elevated serum sex hormone-binding globulin or lower total testosterone levels might be at greater risk for cardiovascular disease.
Therapeutic weight loss is significantly associated with favorable hemodynamic effects in patients with obesity without a history of heart failure.
Patients with type 2 diabetes who have had a cardiovascular event are not adequately prescribed glucose-lowering medications that might prevent subsequent CV events.
Patients with stable ischemic heart disease and diabetes have improved survival when risk factors such as lifestyle behaviors and glycated hemoglobin A1c level are controlled.
Being a younger age at diagnosis of type 2 diabetes is associated with greater risk for total mortality and mortality related to cardiovascular disease outcomes.
Pemafibrate is a safe and effective method for lowering triglyceride and cholesterol levels in patients with type 2 diabetes and hypertriglyceridemia.
Glycemic variability was the strongest independent predictive factor of midterm major adverse cardiac events in patients with diabetes and acute coronary syndrome.
Although congenital heart defects are more frequent in offspring of mothers with overweight or obesity, the relationship between maternal overweight and obesity and risk for complex and specific heart defects is not well defined.
